FDA authorizes new monoclonal treatment that works against omicron
The FDA has authorized a new monoclonal antibody treatment from Eli Lilly called bebtelovimab, an injection which has shown to hold up against omicron and the BA.2 subvariant.
As with other monoclonal therapies, this is for COVID-19 patients early on in their infection who are at high risk for getting severely ill, to help keep them from getting sicker and help keep them out of the hospital.
The Biden administration said it has purchased 600,000 doses for roughly $720 million in anticipation of bebtelovimab getting an emergency use authorization from the FDA.
The plan is to get about 300,000 doses this month and another 300,000 in March. The contract also includes a future option for 500,000 more doses if necessary.
-ABC News' Sasha Pezenik